RUNX1T1 and acute myeloid leukemia: Clinical data from five patients with refractory/relapsed acute myeloid leukemia (AML) and RUNX1::RUNX1T1 fusion gene, treated with venetoclax, cytarabine, and homoharringtonine-based cytoreductive therapy before allogeneic hematopoietic stem cell transplantation (allo-HSCT) at Ruijin Hospital between March 2023 and December 2024, were retrospectively reviewed.